Through adolescence and early adulthood, Lindsay Dow cycled through intensive psychotherapy, repeated hospitalizations, and medications that doctors kept adding or changing — none of it holding.

Diagnosed with bipolar disorder at 13, she spent years in care that never seemed to address the emotional volatility and instability that were upending her life.

“I would go home, take the meds, and basically lie down in my bed and wait for my life to get better,” she recalled. Nearly a decade later, Dow came across descriptions of borderline personality disorder (BPD) and immediately recognized herself in the diagnostic criteria.

When she raised the possibility with her psychiatrist, he agreed the diagnosis might fit but doubted naming it would meaningfully change her care. He was wrong.

Finally diagnosed during an inpatient hospitalization at 24, Dow said the label did what a decade of treatment couldn’t.

Receiving an accurate diagnosis “saved my life,” she said. Years of medication-centered treatment had left her waiting for an external fix. Once BPD was identified, her therapy shifted toward helping her understand her emotions, behaviors, relationships, and sense of self.

Dow’s experience reflects a persistent problem in BPD care: Clinicians often hesitate to name the disorder, even when they suspect it.

As director of the Gunderson Personality Disorders Institute at McLean Hospital, Belmont, Massachusetts, and an Associate Professor of Psychiatry at Harvard Medical School, Boston, Lois Choi-Kain, MD, MEd, sees the consequences of such diagnostic delays every day.

“I can’t tell you how many people have gone back to a doctor they saw for years and said, ‘I have BPD,’ only to hear, ‘I thought that, but I wasn’t sure,’ or ‘You had some traits,’” Choi-Kain said. Others, she added, have been told they were “too smart” or “too nice” to have BPD — responses she describes as deeply damaging.

But growing evidence of sustained remission and a generation of specialized psychotherapies is driving a quiet revolution in how psychiatry views the disorder. Once written off as an untreatable condition best left unnamed, BPD is now recognized as highly responsive to targeted treatment.

Specialized approaches — including dialectical behavior therapy (DBT), mentalization-based therapy, and transference-focused psychotherapy (TFP) — have expanded what clinicians can offer patients.

Major Milestone

A major milestone in this shift arrived in late 2024, when the American Psychiatric Association (APA) published updated practice standards for BPD — the first major revision since 2001.

The new guideline establishes structured psychotherapy as the cornerstone of treatment while firmly discouraging long-term medication for core symptoms. Finding no evidence that drugs resolve underlying features, the APA recommends psychotropic medications only as adjuncts for targeted symptoms like severe anxiety or co-occurring conditions. With roughly half of the patients with BPD taking multiple medications, it advises regular reviews and tapering when appropriate.

The guidance also calls for diagnostic transparency: clinicians are advised to discuss the diagnosis candidly, track progress with standardized tools, and build collaborative treatment plans. Clear communication, the APA says, is both an ethical imperative and fundamental to good care.

Choi-Kain, who helped draft the guidelines, hopes the new standards will push practitioners to abandon historic secrecy.

The evolving clinical consensus reflects decades of research that overturned the long-held view of BPD as a chronic, unremitting diagnosis.

The McLean Study of Adult Development, led by Mary C. Zanarini, EdD, of Harvard Medical School, followed nearly 300 people with BPD over 24 years and found that almost all achieved symptomatic remission for at least 2 years, and 77% sustained that remission for 12 years.

Similarly, the multisite Collaborative Longitudinal Personality Disorders Study followed 668 participants over 10 years, finding that 85% achieved remission lasting at least 1 year, with only about 12% relapsing later.

A Failure in Medical Education

When clinicians know what to look for, BPD need not take years to diagnose. Too few practitioners receive that preparation, a failure in medical education that Frank Yeomans, MD, PhD, clinical professor of psychiatry at Weill Cornell Medical College, New York City, and director of training at its Personality Disorders Institute, called “one of the tragedies” of the field.

“Ten or more years go by where they’re getting the wrong treatments and not getting better — simply wasted years,” Yeomans said.

Even when practitioners spot the signs, Yeomans said, enduring stereotypes of patients as “difficult” or “manipulative” drive many clinicians away from taking on long-term care.

As a result, individuals with BPD commonly wait a decade or longer for an accurate diagnosis. A 2026 study published in the Journal of Psychiatric Research showed a median delay of 13.5 years between symptom onset and formal diagnosis, while targeted surveys examining lived experiences report delays of up to 18 years.

Delays stem in part from what psychiatrist and author Jerold Kreisman, MD, termed BPD’s “chameleon effect.” Kreisman used the concept to describe a dual phenomenon: individuals reflexively alter their identity to match their environment, while the disorder’s shifting symptoms mimic or camouflage conditions like depression, posttraumatic stress disorder, or bipolar disorder.

Because BPD’s mood shifts are rapid and stress-triggered — unlike the sustained, unprovoked episodes of bipolar disorder — the two are easily confused. In one study, nearly 40% of prior bipolar diagnoses in patients with BPD collapsed under structured assessment. The stakes of that confusion could not be higher.

A meta-analysis of nearly 35,000 people with BPD found that 80% experienced suicidal ideation, more than half attempted suicide, and 6% died by suicide — figures that underscore why BPD is recognized as the single strongest independent predictor of suicide risk across all psychiatric conditions.

A key driver behind those staggering numbers, Yeomans warned, is the time spent without appropriate care. During those lost years, destructive behaviors like substance use and self-harm become deeply entrenched while patients remain caught in a revolving door of psychiatric crises.

Time for a New Name?

Marsha Linehan, PhD, who created DBT, a structured therapy originally developed for BPD — likened the condition’s emotional vulnerability to living with severe burns. Without “emotional skin,” even ordinary contact feels excruciating, she said, adding that the disorder also profoundly affects identity, behavior, and relationships.

Since its introduction in the DSM-III in 1980, BPD has been defined by nine diagnostic criteria: fear of abandonment, unstable relationships, identity disturbance, impulsivity, self-harm or recurrent suicidal behavior, emotional reactivity, chronic emptiness, intense anger, and transient, stress-related paranoia or dissociation. Because the diagnostic threshold requires meeting any five markers, presentation is so varied that two individuals can meet criteria while sharing just a single feature.

Beyond that clinical variability, the term “borderline” itself remains deeply controversial. Dating back to the 1930s, the label originally described patients thought to occupy a precarious border between neurosis and psychosis — a concept modern psychiatry has long since abandoned.

Critics call the name vague and stigmatizing, arguing that it conveys little about the actual nature of the condition. Patient advocacy groups have long challenged this terminology. The National Education Alliance for Borderline Personality Disorder, now known as the BPD Alliance, works to reduce diagnostic stigma, while TARA — Treatment and Research Advancements for Borderline Personality Disorder — explicitly advocates for a formal name change. 

Conversely, supporters of retaining the current name point to its established clinical meaning and decades of continuity across diagnosis, research, and treatment. A name change alone, they argue, will not eliminate stigma without a deeper shift in public understanding.

Choi-Kain found the strongest argument for keeping the term within the diagnostic framework itself. “I think BPD is by far the best-written set of criteria for personality disorders,” she said. “When people look at that, most patients invariably say, ‘Yes, I have this.’”

The True Scale of BPD

Earlier research obscured BPD’s prevalence by focusing largely on people already receiving psychiatric care. Within clinical settings, the disorder appears highly prevalent, affecting roughly 22% of psychiatric inpatients and 12% of outpatients.

However, newer studies have looked beyond hospitals and clinics, using community screening to identify individuals who might never enter the mental health system. A 2026 meta-analysis led by Ignacio Ramos-Suárez of the University of Granada pooled community studies and estimated global prevalence at 2.4% — roughly 1 in 40 adults — a figure notably higher than older estimates of 0.5%-2%.

The study also showed that BPD occurs in men and women at roughly equal rates, which is a sharp contrast to clinical settings, where women are diagnosed up to three times as often. This disparity suggests the disorder is widely underrecognized in men, who may instead enter the healthcare system for substance use, aggression, or related behavioral issues.

Choi-Kain argues that because BPD touches such a substantial portion of the population, relying solely on specialty care is no longer a viable public health strategy due to a shortage of trained providers and long waitlists. The solution, she said, is to make BPD treatment widely accessible through everyday practitioners.

The Democratization of Treatment

The late John Gunderson, MD, widely remembered as the “father of BPD,” pioneered a pragmatic way to bring the disorder into routine clinical care. Decades earlier, he had helped transform BPD from a vague psychoanalytic concept into a formally recognized, scientifically grounded DSM diagnosis.

Recognizing that intensive specialty psychotherapies were out of reach for most patients, Gunderson developed General Psychiatric Management (GPM). The model equips psychiatrists, psychologists, social workers, nurses, and primary care clinicians to treat BPD with confidence, without requiring years of advanced specialty training.

GPM emphasizes psychoeducation, practical problem-solving, and what Gunderson called “getting a life.” A central priority is building real-world stability: holding down a job, staying in school, and navigating healthy relationships. Clinicians learn to discuss the diagnosis openly, connect emotional crises to immediate stressors, manage suicidality and self-harm proactively, and use psychiatric medications sparingly for targeted symptoms.

Choi-Kain first worked with Gunderson during a postdoctoral fellowship at McLean Hospital, where they championed diagnostic transparency to challenge the stigma and secrecy surrounding BPD. She views naming the diagnosis as a treatment tool in itself that can demystify the condition and help patients realize their overwhelming emotional storms stem from a recognized disorder rather than a personal failure.

“Whenever I’ve diagnosed someone with BPD, eight times out of ten they embrace it,” Choi-Kain said. “They want help. They know there’s something wrong. I like working with them. That’s what makes them the best patients.”

To expand access to GPM, McLean Hospital and Harvard Medical School created General Psychiatric Management for Borderline Personality Disorder, an 8-hour, CME-accredited online training that is open to a multidisciplinary range of healthcare professionals and clinicians. Covering diagnostic disclosure, treatment structuring, crisis management, and targeted medication use, the self-paced curriculum has drawn more than 15,000 registrations since 2018.

Train-the-trainer programs and residency curricula have further extended the approach into global health systems. In a 2024 Academic Psychiatry study clinicians who completed just 1 day of GPM training demonstrated significantly fewer negative attitudes toward the disorder, a greater willingness to disclose the diagnosis, and increased clinical confidence that sustained at a 6-month follow-up.

Yeomans, whose own work centers on the more intensive TFP, view GPM not as a competitor to specialty treatment but as a means of reaching far more patients.

“I think GPM is a wonderful development, and it should be the first line because it’s less intense. It requires less intensive training,” he said. “More people should be trained in it.” Patients who do not improve with GPM, he added, can then be referred for more specialized care.

A Path to Early Intervention

GPM is now expanding to teenagers, extending structured care to younger patients during critical formative years. Partnering with Carla Sharp, PhD, a professor specializing in adolescent personality psychopathology, Choi-Kain adapted the adult model into the Handbook of Good Psychiatric Management for Adolescents With Borderline Personality Disorder (2022), tailoring the framework for youth and their families.

The approach challenges a deeply ingrained caution in adolescent psychiatry. Clinicians routinely hesitate to diagnose BPD in minors, fearing that standard teenage volatility — mood swings, impulsivity, and a shifting self-image — might be mistaken for a permanent personality disorder. Because of this reluctance, fewer than 10% of practitioners are willing to diagnose the condition in patients younger than 18 years.

Choi-Kain called that hesitation a dangerous mistake. Withholding a diagnosis forces teenagers to navigate developmental milestones without support, frequently derailing school, friendships, and emotional growth.

The adolescent-focused guide steps in while symptoms are still mild and pliable, making family involvement essential. Using practical tools like problem-solving and psychoeducation, clinicians help parents understand that a teenager’s overwhelming reactions often stem from an acute sensitivity to rejection, she said.

This early-intervention framework also lowers the threshold for getting help. Rather than delaying care until a youth meets the full five criteria required for an official diagnosis, clinicians initiate treatment when just three symptoms appear, allowing diagnostic certainty to build over time.

“It’s really on the second episode that you start to generate some certainty about the diagnosis,” Choi-Kain said. “If they rise to having three to five symptoms of BPD or bipolar disorder or depression, it doesn’t matter what the diagnosis is, that young person needs care.”

Remission vs Recovery

Remission occurs when symptoms diminish enough that a person no longer meets the diagnostic threshold for BPD. It is not the same as full recovery. Visible crises like self-harm or impulsivity often recede first, while inner struggles — chronic loneliness, deep emptiness, and severe anxiety — fade much more slowly.

“When we say that someone doesn’t meet the criteria for BPD anymore, that doesn’t mean they’re well,” Yeomans said. “You can get to a point where you don’t have enough symptoms to check off to meet the diagnosis officially, and still not be a satisfied person.”

Data from the McLean Study of Adult Development underscore this divide. The long-term study found that once people achieve a multi-year symptom remission, they rarely relapse into full BPD. Yet true recovery, marked by symptom remission with sustained social and vocational stability, remains fragile. At the 24-year mark, only 37-60% of patients had achieved full functional recovery.

Yeomans noted that long-term stability hinges on something harder to measure building a cohesive identity. Because BPD so often derails a person’s late teens and early twenties, adults in remission frequently struggle to catch up, facing protracted delays in finishing degrees, launching careers, or discovering their own goals and values.

“If you don’t have that stable sense of self, life is going to be much more of a challenge,” Yeomans said. “You’re going to be like a ship at sea without a rudder.”

Guiding patients toward that solid ground is at the heart of the work.

“There’s nothing more satisfying than helping somebody shift from a very sad, frustrated life,” Yeomans said, “to one in which they can enjoy life, be close to people, and find satisfaction in themselves and others.”

Yeomans reported having no relevant financial relationships. Choi-Kain reported receiving income from books and consulting relationships with Tetricus Labs and Parexel-Oryzon.

Carla Cantor is a freelance writer specializing in science, health, and mental health. She most recently served as director of communications for Columbia Psychiatry (Columbia University Irving Medical Center) and the New York State Psychiatric Institute. She is a mentor with NAMI Family Match, a free peer-support program of the National Alliance on Mental Illness.